

Kayentis (global provider of eCOA and DCT solutions) and RWS (language service provider (LSP) and linguistic validation experts) were selected to create and implement the electronic versions of the COAs (eCOAs) on a high priority study with a new client, pioneer in biotechnology.

The study is a Global Small Cell Lung Cancer Phase II Study, spanning 26 languages and 7 instruments, with 100 participating sites.

The long-standing partnership between Kayentis and RWS enabled a successful study start-up so that the final study materials were completed and delivered earlier than quoted timelines.

The collaborative efforts established between both partners helped mitigate any potential delays arising from external review requirements and changing priorities to ensure a successful study.



CASE STUDY

Kayentis
(global provider of eCOA and DCT solutions)

& RWS
(language service provider (LSP) and linguistic validation experts)

Partnering for success

Study Overview

A Global Small Cell Lung Cancer Phase II Study, spanning 26 languages and 7 instruments, with 100 participating sites.

COAs in scope:

- EDRTC Quality of Life Questionnaire - Core 30 (QLQ-C-30)
- EDRTC Quality of Life Questionnaire - Lung Cancer (QLQ-LC)
- EuroQoL Quality of Life - 5 Dimensions - 5 Levels (EQ-5D-5L)
- Functional Assessment of Cancer Therapy - Item GP5 (FACT GP5)
- Patient-Reported Outcomes version of the Common Terminology Criteria for Adverse Events (PRO-CTCAE)
- Patient Global Impression of Change (PGIC)
- Patient Global Impression of Severity (PGIS)

Kayentis and RWS were selected to create and implement the electronic versions of the COAs (eCOAs) on a high priority study with a new client, pioneer in biotechnology.

- The collaborative work on the study involved licensing the COAs and obtaining existing translations, eCOA migration and implementation. In addition, there was paper development required for the PGIC and PGIS for all languages.
- RWS and Kayentis deployed a collaborative process, working simultaneously to ensure a seamless delivery in adherence with the sponsor's timelines.

[Download the case study](#)

[Learn more:](#)



Kayentis & RWS partnering for success

27 July 2022

Kayentis (global provider of eCOA and DCT solutions) and RWS (language service provider (LSP) and

[Read More »](#)



Engage clinical trial participants throughout a trial with our easy-to-use media player embedded in our eCOA app

28 June 2022

Provide clinical trial participants with clear and simple information, anywhere, anytime thanks to the Kayentis

[Read More »](#)



“DCT is not the goal, just the means” webinar

18 June 2022

Using technology to add flexibility to clinical trials can support patients and sites – but

[Read More »](#)



Mitigating the risks of long-term oncology eCOA clinical trials

31 May 2022

Many of the challenges of clinical trials are well known, but oncology trials differ from

[Read More »](#)



Kayentis Media Player, for informed and engaged patients in clinical trials

31 May 2022

Patients taking part in clinical trials need clear and simple information – this is what

[Read More »](#)



Clin'form App: The BYOD solution for all your clinical studies

12 May 2022

Clin'form App is the Kayentis BYOD solution, available for patients and caregivers to facilitate decentralized

[Read More »](#)